Phase 2Completed
Pilot Study Into LDN and NAD+ for Treatment of Patients With Post-COVID-19 Syndrome
Pilot Study Into Low Dose Naltrexone (LDN) and Nicotinamide Adenine Dinucleotide (NAD+) for Treatment of Patients With Post-COVID-19 Syndrome (Long-COVID19)
- Sponsor
- AgelessRx (Industry)
- Enrolment
- 36 enrolled
- Conditions
- Covid19; Long COVID-19; Post-COVID-19 Syndrome
- Interventions
- Naltrexone; NAD+
- Ages
- adults, older adults
- Registry
- NCT04604704
From the registry
Pilot study into low dose naltrexone (LDN) and NAD+ for treatment of patients with post-COVID-19 syndrome.
Primary outcomes
- Reduction of fatigue in post-COVID-19 syndrome by treatment with LDN and NAD+